PROVENGE (sipuleucel-T/lactated ringers solution)
ANTINEOPLASTIC - IMMUNOTHERAPY FOR PROSTATE CANCER · METASTATIC PROSTATE CARCINOMA
DENDREON PHARMA
Drug class
Antineoplastic - Immunotherapy for Prostate Cancer
The category "Antineoplastic - Immunotherapy for Prostate Cancer" is an administrative and clinical grouping rather than a single pharmacologic mechanism class, encompassing immunotherapeutic antineoplastic agents utilized to direct the host immune system against prostate malignancy. Read more about Antineoplastic - Immunotherapy for Prostate Cancer
1 drugs in this class 1 manufacturers
Drugs in Antineoplastic - Immunotherapy for Prostate Cancer
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Immunotherapy for Prostate Cancer preselected. Add indication or manufacturer filters there.
The category "Antineoplastic - Immunotherapy for Prostate Cancer" is an administrative and clinical grouping rather than a single pharmacologic mechanism class, encompassing immunotherapeutic antineoplastic agents utilized to direct the host immune system against prostate malignancy.
Its principal therapeutic role involves stimulating an antitumor immune response, either via autologous cellular immunotherapy—such as sipuleucel-T, which sensitizes antigen-presenting cells against prostatic acid phosphatase—or through immune checkpoint inhibitors targeted against PD-1/PD-L1 pathways in biomarker-selected tumors.
The major disease area for this class is advanced, metastatic castration-resistant prostate cancer, specifically indicated for asymptomatic or minimally symptomatic disease or cases exhibiting microsatellite instability-high, mismatch repair-deficient, or high tumor mutational burden profiles.
-
nih.gov
The category "Antineoplastic - Immunotherapy for Prostate Cancer" is an administrative and clinical grouping rather than a single pharmacologic mechanism class, encompassing immunotherapeutic antineoplastic agents utilized to direct the host immune system against prostate malignancy The major disease area for this class is advanced, metastatic castration-resistant prostate cancer, specifically indicated for asymptomatic or minimally symptomatic disease or cases exhibiting microsatellite instabil...
-
cityofhope.org
The category "Antineoplastic - Immunotherapy for Prostate Cancer" is an administrative and clinical grouping rather than a single pharmacologic mechanism class, encompassing immunotherapeutic antineoplastic agents utilized to direct the host immune system against prostate malignancy Its principal therapeutic role involves stimulating an antitumor immune response, either via autologous cellular immunotherapy—such as sipuleucel-T, which sensitizes antigen-presenting cells against prostatic acid ph...
-
nih.gov
Its principal therapeutic role involves stimulating an antitumor immune response, either via autologous cellular immunotherapy—such as sipuleucel-T, which sensitizes antigen-presenting cells against prostatic acid phosphatase—or through immune checkpoint inhibitors targeted against PD-1/PD-L1 pathways in biomarker-selected tumors The major disease area for this class is advanced, metastatic castration-resistant prostate cancer, specifically indicated for asymptomatic or minimally symptomatic dis...
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.